Amir Sabet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9922744/publications.pdf

Version: 2024-02-01

28 papers	1,242 citations	430874 18 h-index	501196 28 g-index
29 all docs	29 docs citations	29 times ranked	1332 citing authors

#	Article	IF	Citations
1	177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1075-1085.	6.4	37
2	Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride. Cancers, 2022, 14, 557.	3.7	7
3	Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer. Current Oncology, 2022, 29, 4012-4019.	2.2	1
4	Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 103-112.	6.4	27
5	Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. Biomolecules, 2021, 11, 1099.	4.0	14
6	Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Research, 2021, 11, 61.	2.5	16
7	Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement. Cancers, 2021, 13, 4017.	3.7	5
8	Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer. Cancers, 2021, 13, 4193.	3.7	5
9	Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Pharmaceuticals, 2021, 14, 1022.	3.8	1
10	Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. European Radiology, 2017, 27, 966-975.	4.5	25
11	Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1531-1541.	2.5	20
12	Efficacy of peptide receptor radionuclide therapy with Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 74-83.	1.0	23
13	Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1238-1246.	6.4	91
14	Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 370-376.	6.4	52
15	Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 205-210.	6.4	87
16	Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 925-933.	6.4	165
17	Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 505-510.	6.4	76
18	Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸F-FDG PET: Feasibility of a Metabolic Grading System. Journal of Nuclear Medicine, 2014, 55, 1260-1266.	5.0	76

#	Article	IF	Citations
19	Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate. Journal of Nuclear Medicine, 2014, 55, 183-190.	5.0	158
20	Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate. Journal of Nuclear Medicine, 2013, 54, 1857-1861.	5.0	128
21	Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 437-45.	1.0	18
22	May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 4, 80-8.	1.0	4
23	Survival After Accidental Extrahepatic Distribution of Y90 Microspheres to the Mesentery During a Radioembolization Procedure. CardioVascular and Interventional Radiology, 2012, 35, 954-957.	2.0	6
24	Factors predicting outcome of G1/2ÂGEP NET after PRRT with Lu177-octreotate.. Journal of Clinical Oncology, 2012, 30, e14565-e14565.	1.6	1
25	Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 459-466.	6.4	84
26	Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report. Radiation Oncology, 2011, 6, 94.	2.7	27
27	Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate. Journal of Nuclear Medicine, 2011, 52, 1197-1203.	5.0	59
28	Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization. Journal of Nuclear Medicine, 2011, 52, 1063-1067.	5.0	29